Search

Search Results

• 

  Old and new oral anticoagulants for secondary stroke prevention in atrial fibrillation

  Tommaso Sacquegna, Anna Zaniboni, Andrea Rubboli, Gaetano Procaccianti, Michela Crisci, Fabiola Maioli, Giorgia Arnone, Giuseppe Di Pasquale

  314-322

  15-12-2015

  1942

  PDF: 890

  HTML: 1232
• 

  A dangerous adverse event in the use of dabigatran

  Manuel Monti, Giovanni Maria Vincentelli, Francesco Borgognoni, Giuseppe Murdolo, Feliciano Menghini

  250-251

  09-11-2015

  1573

  PDF: 878

  HTML: 254

• The incidence of bleeding in patients with nonvalvular atrial fibrillation using anticoagulants: a real-world report with the biggest Vietnamese data

  Bui The Dung, Cao Ngoc Mai Han, Tran Hoa, Nguyen Thanh Hien

  17-02-2025

  1559

  PDF: 70

  HTML: 0

• Assessment and predictors of inappropriate dose of direct oral anticoagulants

  Mosaad O. Almegren

  09-01-2024

  826

  pdf: 390

  HTML: 117
• 

  Pharmacology of new oral anticoagulants: mechanism of action, pharmacokinetics, pharmacodynamics

  Luca Masotti, Mauro Campanini

  1-7

  24-12-2013

  10376

  PDF: 2809
• 

  The practical management of bleedings during treatment with direct oral anticoagulants: the emergency reversal therapy

  Luca Masotti, Giancarlo Landini, Grazia Panigada

  48-58

  24-12-2013

  1349

  PDF: 918
• 

  Dabigatran etexilate: a direct thrombin inhibitor

  M. Dugnani

  56-62

  03-05-2013

  893

  PDF: 1446
• 

  Efficacy and safety of new oral anticoagulants compared with warfarin in cardioembolic prophylaxis of patients with non valvular atrial fibrillation. More lights than shadows

  Luca Masotti, Mario Di Napoli, Walter Ageno, Davide Imberti, Daniel Godoy, Grazia Panigada, Niccolò Napoli, Giancarlo Landini, Roberto Cappelli, Ido Iori, Domenico Prisco, Giancarlo Agnelli

  153-169

  23-10-2012

  1662

  PDF: 1959
• 

  Newer non-vitamin K-antagonist direct oral anticoagulants in acute coronary syndromes

  Andrea Rubboli

  22-28

  24-12-2013

  983

  PDF: 724
• 

  New anticoagulant drugs versus warfarin in atrial fibrillation: economic evaluation and cost-effectiveness analysis

  Mauro Silingardi

  65-70

  24-12-2013

  1326

  PDF: 932
• 

  New oral anticoagulants: key messages for clinicians

  Matteo Giorgi-Pierfranceschi, Chiara Cattabiani, Francesco Dentali

  74-84

  24-12-2013

  1252

  PDF: 862
• 

  Direct oral anticoagulants for secondary prevention in patients with non-valvular atrial fibrillation

  Luca Masotti, Mario Di Napoli, Walter Ageno, Davide Imberti, Cecilia Becattini, Maurizio Paciaroni, Daniel Augustin Godoy, Roberto Cappelli, Giancarlo Landini, Grazia Panigada, Ido Iori, Domenico Prisco, Giancarlo Agnelli

  8-21

  24-12-2013

  1300

  PDF: 851
• 

  Direct oral anticoagulants in real practice: which doses for which patients. Limitations and bleeding risk compared to vitamin K antagonists

  Giancarlo Landini, Luca Masotti

  41-47

  24-12-2013

  904

  PDF: 786
• 

  Monitoring strategies for patients treated with the new oral anticoagulants and the need for laboratory evaluation of hemostasis

  Andrea Fontanella, Pierpaolo Di Micco

  59-64

  24-12-2013

  921

  PDF: 896
• 

  Cryptogenic strokes and embolic strokes of unknown source: lights and shadows of a new construct

  Marco Masina

  171-174

  30-09-2016

  1402

  PDF: 849

  HTML: 635
• 

  The treatment of venous thromboembolism with new oral anticoagulants

  Davide Imberti

  29-35

  24-12-2013

  1053

  PDF: 828
• 

  How to manage new oral anticoagulants in case of surgery

  Davide Imberti

  36-40

  24-12-2013

  897

  PDF: 807

• Pharmacological interactions in novel oral anticoagulants, statins, and hypertension drugs in patients treated with direct-acting antivirals for hepatitis C: a Delphi Consensus project

  Ivan Gentile, Giancarlo Agnelli, Angelo Avogaro, Claudio Borghi, Alessia Ciancio, Ernesto Claar, Patrizio Pasqualetti, Pasquale Perrone Filardi

  25-11-2024

  902

  PDF: 317

  SUPPLEMENTARY MATERIAL: 215

  ACKNOWLEDGMENTS: 206

  HTML: 101
• 

  Cryptogenic stroke

  Michele Stornello, Roberto Cappellani, Giuseppe Micieli, Simona Sacco, Stefano Spolveri, Roberto Sterzi, Danilo Toni, Antonio Carolei

  185-194

  30-09-2016

  1878

  PDF: 1088

  HTML: 584

• Retrospective analysis on clinical characteristics and venous thromboembolism outcomes using bridging prophylaxis with low molecular weight heparin for thrombophilic women performing oocyte retrieval for assisted reproductive procedures: 15 years of experience

  Pierpaolo Di Micco, Corrado Lodigiani, Lidia Luciana Rota, Giuseppe Camporese, Ida Strina, Carlo Alviggi

  17-06-2024

  416

  PDF: 261

  HTML: 29
• 

  A review on management of antiphospholipid syndrome in clinical practice

  Carmine Siniscalchi, Pietro Rossetti, Gaetano Carolla, Pierpaolo Di Micco, Adriano Stella, Michele Riva

  13-09-2023

  2371

  PDF: 979

  HTML: 78
• 

  Optimal duration of anticoagulant therapy in patients with venous thromboembolism

  Gualtiero Palareti

  235-244

  14-09-2018

  1470

  PDF: 1743

  HTML: 260
• 

  Stroke prevention in atrial fibrillation: findings from Tuscan FADOI Stroke Registry

  Luca Masotti, Rinaldo Innocenti, Stefano Spolveri, Irene Chiti, Grazia Panigada, Cristiana Seravalle, Giancarlo Landini, Alberto Fortini, Rino Migliacci, Raffaele Laureano, for Tuscan FADOI Stroke Registry Investigators

  134-140

  12-06-2014

  1555

  PDF: 1218

  Appendix: 566

  HTML: 622
• 

  Young FADOI and gender medicine: sex gender differences in cardiovascular disease

  Tiziana Ciarambino, Miriam Gino, Paola Gnerre, Elena Barbagelata, Nunzia Barone, Francesca Saladini, Federica Lorenzi, Marta Zanon, Maria Cristina Pasquini, Cecilia Politi

  23-31

  20-03-2018

  2600

  PDF: 1103

  HTML: 474
• 

  Embolic stroke of undetermined source: a retrospective analysis from an Italian Stroke Unit

  Marco Masina, Annalena Cicognani, Carla Lofiego, Simona Malservisi, Riccardo Parlangeli, Alessandro Lombardi

  202-206

  30-09-2016

  1620

  PDF: 821

  HTML: 803